BOSTON SCIENTIFIC CORP (BSX) Form 8-K — Oct 28, 2026
Boston Scientific reported Q3 2026 net sales of $5.138 billion, up 1.5% on a reported, operational and organic basis, with GAAP EPS of $0.40 (down from $0.51 a year ago) and adjusted EPS of $0.73 (vs $0.75). Neuromodulation grew 13.1% while Urology and Endoscopy declined. The company cut near-term expectations, guiding Q4 2026 net sales to DECLINE 1-3% versus the prior year, and narrowed full-year adjusted EPS guidance to $3.16-$3.18. CEO Mike Mahoney acknowledged a challenging year, citing the August 2026 cybersecurity incident that disrupted operations.
Key figures
- Eps
- 0.4
- Revenue
- 5138000000
- Guidance
- FY2026 net sales growth ~4.25% reported / ~3.75% organic; FY adjusted EPS $3.16-$3.18; Q4 2026 net sales decline of (3.0)% to (1.0)% reported and organic; Q4 adjusted EPS $0.77-$0.79
- Net Income
- 582000000
- Revenue Yoy
- 1.5%
- Adjusted EPS
- $0.73 vs $0.75 prior year
- Segment Growth
- MedSurg +0.6% reported; Cardiovascular +1.9% reported; Neuromodulation +13.1%; Urology -3.2%; Endoscopy -0.8%
- Regional Growth
- US +0.5%; EMEA +4.4%; APAC -0.6%; LACA +16.0%
- Q3 2025 revenue
- 5065000000
- Prior Year GAAP EPS
- $0.51
- Cybersecurity Incident
- August 2026 incident first reported August 26, 2026
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.